Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Clinical pharmacology of imeglimin for the treatment of type 2 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Non-insulin pharmacological therapies for treating type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Exenatide: pharmacokinetics, clinical use, and future directions

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Management of cardiovascular disease in patients with psoriasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Treatment with non-steroidal anti-inflammatory drugs in patients after myocardial infarction - a systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Introduction: With the rising prevalence of type 2 diabetes (T2D), there is a substantial interest in novel, glucose-lowering drugs that may complement existing treatment options. Imeglimin is an oral antidiabetic agent currently in clinical development.Areas covered: This review is based on a literature search using PubMed and Embase including all published manuscripts and presentations concerning imeglimin. Supplementary information was retrieved from the manufacturer's official webpage. Preclinical and clinical data are summarized with a focus on mechanisms of action as well as clinical efficacy and safety in T2D.Expert opinion: Imeglimin's mode of action seems to be improved mitochondrial function in pancreatic beta cells leading to improved insulin secretion and lowering of plasma glucose levels. In clinical trials of up to 24 weeks, imeglimin in doses of 1,000-1,500 mg twice daily conferred modest reductions in glycates hemoglobin A1c of 6-11 mmol/mol (0.5-1.0%) (placebo-adjusted) as a monotherapy and 7 mmol/mol (0.6%) as an add-on therapy to metformin or sitagliptin in patients with T2D. Reported adverse effects were mainly gastrointestinal discomfort. The position of imeglimin among other pharmacotherapies in the treatment of T2D will be determined based on future studies more clearly outlining the safety and long-term cardiovascular effects.Abbreviations: AUC: area under the curve; BID: twice daily; DPP-4: dipeptidyl peptidase 4; GLP-1R: glucagon-like peptide-1 receptor; HbA1c: glycated hemoglobin A1c; HFHSD: high-fat high-sucrose diet; OAD: oral antidiabetic; OD: once daily; OGTT: oral glucose tolerance test; PPAR-γ: peroxisome proliferator-activated receptor gamma; PTP: permeability transition pore; SGLT-2: sodium-glucose transport protein 2; STZ: streptozotocin; T2D: type 2 diabetes.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Pharmacotherapy
Sider (fra-til)1-12
Antal sider12
ISSN1465-6566
DOI
StatusE-pub ahead of print - 28 feb. 2020

ID: 59467655